Seems odd to me that after the ridiculous short attack article followed by emotional panic-selling, there were fervent calls for insiders to buy. Dr. Chan made a relatively huge purchase by exercising his options early. Other than a couple posts, none of those who usually rail against him and were requesting insider purchases said anything. Of all the things that happened over the last couple weeks, Dr. Chan’s large purchase was the most significant and telling. I’m looking forward to Hemodefend news soon and hopefully, at some point, a study partnership with regard to CRS in CAR-T therapy. News of that nature would be a huge boost, in my opinion.